

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
*( Not for submission under 37 CFR 1.99)*

Application Number		10862769
Filing Date		2006-06-27
First Named Inventor		Sam Philip Heywood
Art Unit		1643
Examiner Name		David J. Blanchard
Attorney Docket Number		07-1048-WO-US

**U.S.PATENTS**

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

**U.S.PATENT APPLICATION PUBLICATIONS**

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20060171940	A1	2006-08-03	Mozier et al.	
	2	20060110382	A1	2006-05-25	Mozier	

If you wish to add additional U.S. Published Application citation information please click the Add button.

**FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> <sup>j</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10862769
Filing Date	2006-06-27
First Named Inventor	Sam Philip Heywood
Art Unit	1643
Examiner Name	David J. Blanchard
Attorney Docket Number	07-1048-WO-US

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	COGNE, Michel et al.: "Structurally Abnormal Immunoglobulins in Human Immunoproliferative Disorders," The Journal of The American Society of Hematology, Vol. 79, No. 9, May 1, 1992, pages 2181-2195.	<input type="checkbox"/>
	2	STEINER, Lisa A. et al.: "Amino Acid Sequence of the Heavy-Chain Variable Region of the Crystallizable Human Myeloma Protein Dob," Biochemistry, Vol. 18, No. 19, 1979, pages 4068-4080.	<input type="checkbox"/>
	3	BRADWELL, Arthur R. et al.: "Serum test for assessment of patients with Bence Jones myeloma," THE LANCET, Vol. 361, February 8, 2003, www.thelancet.com, pages 489-491.	<input type="checkbox"/>
	4	STEINER, Lisa A. et al.: "The Crystallizable Human Myeloma Protein Dob Has a Hinge-Region Deletion," Biochemistry, Vol. 18, No. 19, 1979, pages 4044-4067.	<input type="checkbox"/>
	5	BEGG, Gillian E. and SPEICHER, David W.: "Mass Spectrometry Detection and Reduction of Disulfide Adducts Between Reducing Agents and Recombinant Proteins With Highly Reactive Cysteins," Journal of Biomolecular Techniques, 10:17-20, 1999.	<input type="checkbox"/>
	6	GRASSETTI, D.R. and MURRAY, J.F. JR.: "Determination of Sulphydryl Groups with 2,2'- or 4,4' - Dithiodipyridine," Archives of Biochemistry and Biophysics, 119, pages 41-49 (1967).	<input type="checkbox"/>
	7	CAI, Kewen et al.: "Structure and function in rhodopsin: Topology of the C-terminal polypeptide chain in relation to the cytoplasmic loops," Proc. Natl. Acad. Sci., Vol. 94, pages 14267-14272, December 1997, Biochemistry.	<input type="checkbox"/>
	8	CAI, Kewen et al.: "Single-Cysteine Substitution Mutants at Amino Acid Positions 306-321 in Rhodopsin, the Sequence between the Cytoplasmic End of Helix VII and the Palmitoylation Sites: Sulphydryl Reactivity and Transducin Activation Reveal a Tertiary Structure," Biochemistry 1999, 38, 7925-7930.	<input type="checkbox"/>
	9	HUMPHREYS, David P. et al.: "Alternative antibody Fab' fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering," Protein Engineering, Design & Selection, Vol. 20, No. 5, pages 227-234, 2007.	<input type="checkbox"/>
	10	ROTHLISBERGER, Daniela et al.: "Domain Interactions in the Fab Fragment: A comparative Evaluation of the single-chain Fv and Fab Format Engineered with Variable Domains of Different Stability," J. Mol. Biol. (2005), 347, pages 773-789.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10862769
Filing Date	2006-06-27
First Named Inventor	Sam Philip Heywood
Art Unit	1643
Examiner Name	David J. Blanchard
Attorney Docket Number	07-1048-WO-US

11	HUMPHREYS, David P. et al.: "F(ab')2 molecules made from Escherichia coli produced Fab' with hinge sequences conferring increased serum survival in an animal model," Journal of Immunological Methods 217 (1998) 1-10.	<input type="checkbox"/>
12	HONG, R. and NISONOFF, A.: "Relative Labilities of the Two Types of Interchain Disulfide Bond of Rabbit yG-Immunoglobulin," The Journal of Biological Chemistry, Vol. 240, No. 10, October 1965, pages 3883-3891.	<input type="checkbox"/>
13	ANGAL, S. et al.: "A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody," Molecular Immunology, Vol. 30, No. 1, pages 105-108, 1993.	<input type="checkbox"/>
14	AALBERSE, Rob C. et al.: "The Apparent Monovalency of Human IgG4 Is Due to Bispecificity," International Archives of Allergy and Immunology, 1999, 118 (2-4) : 187-189.	<input type="checkbox"/>
15	PEDLEY, R.B. et al.: "The potential for enhanced tumor localisation by poly(ethylene glycol) modification of anti-CEA antibody," BR. J. Cancer (1994), 70, pages 1126-1130.	<input type="checkbox"/>
16	KING, David J. et al.: "Improved Tumor Targeting with Chemically Cross-Linked Recombinant Antibody Fragments," Cancer Research 54, 6176-6185, December 1, 1994.	<input type="checkbox"/>
17	DELGADO, C. et al.: "Enhanced tumor specificity of an anti-carcinoembryonic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification," British Journal of Cancer (1996) 73, 175-182.	<input type="checkbox"/>
18	Dall'Acqua, William et al.: "Contribution of Domain Interface Residues to the Stability of Antibody CH3 Domain Homodimers," Biochemistry 1998, 37, 9266-9273.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.